Therapeutic advances in cardiac targeted drug delivery: from theory to practice

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e526–e528.
   Web of Science ®Google Scholar
• Roth GA, Johnson CO, Abate KH, et al. The burden of cardiovascular diseases among US States, 1990-2016. JAMA Cardiol. 2018;3(5):375–389.
   PubMed Web of Science ®Google Scholar
• WHO. Global status report on noncommunicable diseases 2014. Geneva (Switzerland): World Health Organization; 2014.
   Google Scholar
• Leong YY, Ng WH, Ellison-Hughes GM, et al. Cardiac stem cells for myocardial regeneration: they are not alone. Front Cardiovasc Med. 2017;4:47.
   PubMed Web of Science ®Google Scholar
• Saludas L, Pascual-Gil S, Roli F, et al. Heart tissue repair and cardioprotection using drug delivery systems. Maturitas. 2018;110:1–9.
   PubMed Web of Science ®Google Scholar
• Liu Z, Mikrani R, Zubair HM, et al. Systemic and local delivery of mesenchymal stem cells for heart renovation: challenges and innovations. Eur J Pharmacol. 2020;876:173049.
   PubMed Web of Science ®Google Scholar
• Segura-Ibarra V, Cara FE, Wu S, et al. Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention. J Control Release. 2017;262:18–27.
   PubMed Web of Science ®Google Scholar
• Li SY, Sun R, Wang HX, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release. 2015;205:7–14.
   PubMed Web of Science ®Google Scholar
• Abri Aghdam M, Bagheri R, Mosafer J, et al. Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release. J Control Release. 2019;315:1–22.
   PubMed Web of Science ®Google Scholar
• Allijn IE, Czarny BMS, Wang X, et al. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J Control Release. 2017;247:127–133.
   PubMed Web of Science ®Google Scholar
• Ali DC, Naveed M, Gordon A, et al. β-Adrenergic receptor, an essential target in cardiovascular diseases. Heart Fail Rev. 2020;25(2):343–354.
   PubMed Web of Science ®Google Scholar
• Naveed M, Han L, Hasnat M, et al. Suppression of TGP on myocardial remodeling by regulating the NF-κB pathway. Biomed Pharmacother. 2018;108:1460–1468.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
   PubMed Web of Science ®Google Scholar
• Bax JJ, Achenbach S, Valgimigli M, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477.
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673–692.
   PubMed Web of Science ®Google Scholar
• Karimi M, Bahrami S, Ravari SB, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–1623.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomed. 2009;4 :99–105.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chan G, Hu Y, et al. A comprehensive map of FDA-approved pharmaceutical products. Pharmaceutics. 2018;10(4):263.
   PubMed Web of Science ®Google Scholar
• Karimi M, Ghasemi A, Sahandi Zangabad P, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457–1501.
   PubMed Web of Science ®Google Scholar
• Dariva CG, Coelho JFJ, Serra AC. Near infrared light-triggered nanoparticles using singlet oxygen photocleavage for drug delivery systems. J Control Release. 2019;294:337–354.
   PubMed Web of Science ®Google Scholar
• Hu Q, Chen Q, Gu Z. Advances in transformable drug delivery systems. Biomaterials. 2018;178:546–558.
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191.
   PubMed Web of Science ®Google Scholar
• Nakhlband A, Eskandani M, Saeedi N, et al. Marrubiin-loaded solid lipid nanoparticles’ impact on TNF-α treated umbilical vein endothelial cells: a study for cardioprotective effect. Colloids Surf B Biointerfaces. 2018;164:299–307.
   PubMed Web of Science ®Google Scholar
• Nguyen MM, Carlini AS, Chien MP, et al. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv Mater Weinheim. 2015;27(37):5547–5552.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zu Y, Dhanasekara CS, et al. Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(1):e1412.
   Web of Science ®Google Scholar
• Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119(1):159–176.
   PubMed Web of Science ®Google Scholar
• Nakhlband A, Eskandani M, Omidi Y, et al. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective. Bioimpacts. 2018;8(1):59–75.
   PubMed Web of Science ®Google Scholar
• Karimi M, Sahandi Zangabad P, Baghaee-Ravari S, et al. Smart nanostructures for cargo delivery: uncaging and activating by light. J Am Chem Soc. 2017;139(13):4584–4610.
   PubMed Web of Science ®Google Scholar
• Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ. 2003;327(7423):1075.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hutin YJ, Bulterys M, et al. Injection practices in 2011-2015: a review using data from the demographic and health surveys (DHS). BMC Health Serv Res. 2019;19(1):600.
   PubMed Web of Science ®Google Scholar
• Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation. 2005;112(10):1451–1461.
   PubMed Web of Science ®Google Scholar
• Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863–868.
   PubMed Web of Science ®Google Scholar
• Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107(16):2134–2139.
   PubMed Web of Science ®Google Scholar
• Chin B, Nakamoto Y, Bulte J, et al. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun. 2003;24(11):1149–1154.
   PubMed Web of Science ®Google Scholar
• Ferreira MP, Ranjan S, Correia AM, et al. In vitro and in vivo assessment of heart-homing porous silicon nanoparticles. Biomaterials. 2016;94:93–104.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Control Release. 2014;190:531–541.
   PubMed Web of Science ®Google Scholar
• Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release. 2004;100(1):111–119.
   PubMed Web of Science ®Google Scholar
• Torrieri G, Fontana F, Figueiredo P, et al. Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction. Nanoscale. 2020;12(4):2350–2358.
   PubMed Web of Science ®Google Scholar
• Chen S, Grayburn PA. Ultrasound-targeted microbubble destruction for cardiac gene delivery. cardiac gene therapy. Methods Mol Biol. 2017;1521:205–218.
   PubMedGoogle Scholar
• Kim J, Cao L, Shvartsman D, et al. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 2011;11(2):694–700.
   PubMed Web of Science ®Google Scholar
• Shabbir A, Zisa D, Leiker M, et al. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation. 2009;87(9):1275–1282.
   PubMed Web of Science ®Google Scholar
• Shabbir A, Zisa D, Suzuki G, et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol. 2009;296(6):H1888–H1897.
   PubMed Web of Science ®Google Scholar
• Shabbir A, Zisa D, Lin H, et al. Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol. 2010;299(5):H1428–H1438.
   PubMed Web of Science ®Google Scholar
• Zisa D, Shabbir A, Mastri M, et al. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol. 2009;297(5):R1503–R1515.
   PubMed Web of Science ®Google Scholar
• Zisa D, Shabbir A, Mastri M, et al. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. Am J Physiol Heart Circ Physiol. 2011;301(6):H2422–H2432.
   PubMed Web of Science ®Google Scholar
• Mao C, Hou X, Wang B, et al. Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats. Stem Cell Res Ther. 2017;8(1):18.
   PubMedGoogle Scholar
• Cimmino G, Giannarelli C, Chen W, et al. Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice: comparison of intramuscular and intravenous administration. Cardiovasc Pharmacol. 2011;57(3):325–333.
   PubMed Web of Science ®Google Scholar
• Ishikawa K. Intracoronary injection of large stem cells: size matters. Circ Cardiovasc Interventions. 2015;8(5):649–658.
   Web of Science ®Google Scholar
• Gastl M, Sürder D, Corti R, et al. Effect of intracoronary bone marrow-derived mononuclear cell injection early and late after myocardial infarction on CMR-derived myocardial strain. Int J Cardiol. 2020;310:108–115.
   PubMed Web of Science ®Google Scholar
• Haddad K, Potter B, Matteau A, et al. Long-term follow-up of the compare-ami trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction with left ventricular dysfunction. Canadian J Cardiol. 2018;34(10):S141.
   Google Scholar
• Eslam RB, Musmann R, Waxman AB, et al. Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension. Cytotherapy. 2017;19(6):668–679.
   PubMed Web of Science ®Google Scholar
• Guariento A, Blitzer D, Doulamis I, et al. Preischemic autologous mitochondrial transplantation by intracoronary injection for myocardial protection. J Thorac Cardiovasc Surg. 2020;160(2):e15–e29.
   PubMed Web of Science ®Google Scholar
• Lamirault G, Bock E, Sébille V, et al. Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. Qual Life Res. 2017;26(1):121–125.
   PubMed Web of Science ®Google Scholar
• Balaban Y, Kaya A, Satilmisoglu MH, et al. Intracoronary focal nitroglycerin injection through drilled balloon is very effective in the resolution of coronary spasm versus into proximal coronary artery: a prospective randomized comparison study. Interventional Cardiol. 2018;31(6):765–774.
   Google Scholar
• Park CB, Cho JM, Kim DH, et al. Intracoronary nitroglycerin injection through a microcatheter for coronary no-reflow following percutaneous coronary intervention. Int J Cardiol. 2016;214:400–402.
   PubMed Web of Science ®Google Scholar
• Abu Arab T, Rafik R, El Etriby A. Efficacy and safety of local intracoronary drug delivery in treatment of no-reflow phenomenon: a pilot study. J Interv Cardiol. 2016;29(5):496–504.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zeng J, Huang H. Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction. Int J Cardiol. 2016;208:137–140.
   PubMed Web of Science ®Google Scholar
• De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222(2):426–433.
   PubMed Web of Science ®Google Scholar
• Nab MH, Mostafa S, Institute NH, et al. Comparison between intracoronary and intravenous eptifibatide bolus injection regimens during primary PCI in patients presenting with anterior STEMI. Cardiovasc Interventions. 2017;10(3):S8.
   Web of Science ®Google Scholar
• Rodriguez ER, Tan CD. Structure and anatomy of the human pericardium. Prog Cardiovasc Dis. 2017;59(4):327–340.
   PubMed Web of Science ®Google Scholar
• Ristic AD, Wagner HJ, Maksimovic R, et al. Epicardial halo phenomenon: a guide for pericardiocentesis? Heart Fail Rev. 2013;18(3):307–316.
   PubMed Web of Science ®Google Scholar
• Sinnaeve PR, Adriaenssens T. A contemporary look at pericardiocentesis. Trends Cardiovasc Med. 2019;29(7):375–383.
   PubMed Web of Science ®Google Scholar
• Maggiolini S, De Carlini CC, Imazio M. Evolution of the pericardiocentesis technique. J Cardiovasc Med. 2018;19(6):267–273.
   Google Scholar
• Ayers GM, Rho TH, Ben-David J, et al. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. Cardiovasc Electrophysiol. 1996;7(8):713–721.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu Z, Fan Z, et al. Pericardial application as a new route for implanting stem-cell cardiospheres to treat myocardial infarction. J Physiol. 2018;596(11):2037–2054.
   PubMed Web of Science ®Google Scholar
• Blazquez R, Sanchez-Margallo FM, Crisostomo V, et al. Intrapericardial delivery of cardiosphere-derived cells: an immunological study in a clinically relevant large animal model. PLoS One. 2016;11(2):e0149001.
   PubMed Web of Science ®Google Scholar
• Lamping KG, Rios CD, Chun JA, et al. Intrapericardial administration of adenovirus for gene transfer. 1997;272(1):H310–H317.
   Google Scholar
• Wang W, Wang MQ, Wang H, et al. Effects of adenovirus-mediated hepatocyte growth factor gene therapy on postinfarct heart function: comparison of single and repeated injections. Hum Gene Ther. 2016;27(8):643–651.
   PubMed Web of Science ®Google Scholar
• Laakmann S, Fortmuller L, Piccini I, et al. Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(3):227–238.
   PubMed Web of Science ®Google Scholar
• Numico G, Cristofano A, Occelli M, et al. Prolonged drainage and intrapericardial bleomycin administration for cardiac tamponade secondary to cancer-related pericardial effusion. Medicine. 2016;95(15):e3273.
   PubMed Web of Science ®Google Scholar
• Ramer SA, Sapp JL. Percutaneous intrapericardial injection of triamcinolone in a patient with incessant pericarditis: a novel technique. Can J Cardiol. 2013;29(6):751.e1.
   Web of Science ®Google Scholar
• Hou D, Rogers PI, Toleikis PM, et al. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation. 2000;102(13):1575–1581.
   PubMed Web of Science ®Google Scholar
• Laham RJ, Rezaee M, Post M, et al. Intrapericardial administration of basic fibroblast growth factor: myocardial and tissue distribution and comparison with intracoronary and intravenous administration. Catheter Cardiovasc Interv. 2003;58(3):375–381.
   PubMed Web of Science ®Google Scholar
• Kolettis TM, Kazakos N, Katsouras CS, et al. Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine. Int J Cardiol. 2005;99(3):415–421.
   PubMed Web of Science ®Google Scholar
• Zhang M, Methot D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33(5):907–921.
   PubMed Web of Science ®Google Scholar
• Muller-Ehmsen J, Whittaker P, Kloner RA, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol. 2002;34(2):107–116.
   PubMed Web of Science ®Google Scholar
• Burkhart HM, Qureshi MY, Rossano JW, et al. Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. J Thorac Cardiovasc Surg. 2019;158(6):1614–1623.
   PubMed Web of Science ®Google Scholar
• Richardson JD, Psaltis PJ, Frost L, et al. Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy. 2014;16(4):460–470.
   PubMed Web of Science ®Google Scholar
• Andrie RP, Beiert T, Knappe V. Treatment with mononuclear cell populations improves post-infarction cardiac function but does not reduce arrhythmia susceptibility. PLoS One. 2019;14(2):e0208301.
   PubMed Web of Science ®Google Scholar
• O’Quinn MP, Dormer KJ, Huizar JF, et al. Epicardial injection of nanoformulated calcium into cardiac ganglionic plexi suppresses autonomic nerve activity and postoperative atrial fibrillation. Heart Rhythm Society. 2019;16(4):597–605.
   PubMed Web of Science ®Google Scholar
• Grossman PM, Han Z, Palasis M, et al. Incomplete retention after direct myocardial injection. Cathet Cardiovasc Intervent. 2002;55(3):392–397.
   PubMed Web of Science ®Google Scholar
• Greenberg JW, Lancaster TS, Schuessler RB, et al. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017;52(4):665–672.
   PubMed Web of Science ®Google Scholar
• Romanov A, Pokushalov E, Ponomarev D, et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: three-year follow-up of a randomized study. Heart Rhythm. 2019;16(2):172–177.
   PubMed Web of Science ®Google Scholar
• Mathieu E, Lamirault G, Toquet C, et al. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7(12):e51991.
   PubMed Web of Science ®Google Scholar
• Johnson TD, Christman KL. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv. 2013;10(1):59–72.
   PubMed Web of Science ®Google Scholar
• Zeng X, Zou L, Levine RA, et al. Efficacy of polymer injection for ischemic mitral regurgitation: persistent reduction of mitral regurgitation and attenuation of left ventricular remodeling. JACC Cardiovasc Interv. 2015;8(2):355–363.
   PubMed Web of Science ®Google Scholar
• Teng CJ, Luo J, Chiu RC, et al. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132(3):628–632.
   PubMed Web of Science ®Google Scholar
• Bonnet G, Ishikawa K, Hajjar RJ, et al. Direct myocardial injection of vectors. Methods Mol Biol. 2017;1521:237–248.
   PubMedGoogle Scholar
• Chen J, Guo R, Zhou Q, et al. Injection of composite with bone marrow-derived mesenchymal stem cells and a novel synthetic hydrogel after myocardial infarction: a protective role in left ventricle function. Kaohsiung J Med Sci. 2014;30(4):173–180.
   PubMed Web of Science ®Google Scholar
• Mihic A, Cui Z, Wu J, et al. A conductive polymer hydrogel supports cell electrical signaling and improves cardiac function after implantation into myocardial infarct. Circulation. 2015;132(8):772–784.
   PubMed Web of Science ®Google Scholar
• Cui Z, Ni NC, Wu J, et al. Polypyrrole-chitosan conductive biomaterial synchronizes cardiomyocyte contraction and improves myocardial electrical impulse propagation. Theranostics. 2018;8(10):2752–2764.
   PubMed Web of Science ®Google Scholar
• Liao S-Y, Siu C-W, Liu Y, et al. Attenuation of left ventricular adverse remodeling with epicardial patching after myocardial infarction. J Cardiac Failure. 2010;16(7):590–598.
   PubMed Web of Science ®Google Scholar
• D’Amore A, Yoshizumi T, Luketich SK, et al. Bi-layered polyurethane - extracellular matrix cardiac patch improves ischemic ventricular wall remodeling in a rat model. Biomaterials. 2016;107:1–14.
   PubMed Web of Science ®Google Scholar
• Qazi TH, Rai R, Dippold D, et al. Development and characterization of novel electrically conductive PANI-PGS composites for cardiac tissue engineering applications. Acta Biomater. 2014;10(6):2434–2445.
   PubMed Web of Science ®Google Scholar
• Dergilev KV, Tsokolayeva ZI, Beloglazova IB, Ratner EI, et al. [Epicardial transplantation of cardiac progenitor cells based cells sheets is more promising method for stimulation of myocardial regeneration, than conventional cell injections]. Kardiologiia. 2019;59(5):53–60.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim RY, Park BW, et al. Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction. Nat Commun. 2019;10(1):3123.
   PubMedGoogle Scholar
• Whyte W, Roche ET, Varela CE, et al. Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir. Nat Biomed Eng. 2018;2(6):416–428.
   PubMed Web of Science ®Google Scholar
• Tano N, Narita T, Kaneko M, et al. Epicardial placement of mesenchymal stromal cell-sheets for the treatment of ischemic cardiomyopathy; in vivo proof-of-concept study. Mol Ther. 2014;22(10):1864–1871.
   PubMed Web of Science ®Google Scholar
• Patila T, Miyagawa S, Imanishi Y, et al. Comparison of arrhythmogenicity and proinflammatory activity induced by intramyocardial or epicardial myoblast sheet delivery in a rat model of ischemic heart failure. PLoS One. 2015;10(4):e0123963.
   PubMed Web of Science ®Google Scholar
• Chaudhry PA, Mishima T, Sharov VG, et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Soc Thoracic Surg. 2000;70(4):1275–1280.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Yambe T, Sekine K, et al. Development of an artificial myocardium using a covalent shape-memory alloy fiber and its cardiovascular diagnostic response. Paper presented at Engineering in Medicine and Biology 27th Annual Conference; 2005 September 1–4; Shanghai, China.
   Google Scholar
• Mau J, Menzie S, Huang Y, et al. Nonsurround, nonuniform, biventricular-capable direct cardiac compression provides Frank-Starling recruitment independent of left ventricular septal damage. J Thorac Cardiovasc Surg. 2011;142(1):209–215.
   PubMed Web of Science ®Google Scholar
• Zhou X. Active hydraulic ventricular attaching support system, US. Google Patents, WO2010127553A1. 2010. https://patents.google.com/patent/US20120059214.
   Google Scholar
• Sembatya KR, Gang W, Muhammad N, et al. Cardioprotective effect of silicone built restraint device (ASD), for left ventricle remodeling in rat heart failure models. 2020.DOI:10.22541/au.158888126.60534417.
   Google Scholar
• Naveed M, Wenhua L, Gang W, et al. A novel ventricular restraint device (ASD) repetitively deliver Salvia miltiorrhiza to epicardium have good curative effects in heart failure management. Biomed Pharmacother. 2017;95:701–710.
   PubMed Web of Science ®Google Scholar
• Yasmeen S, Liao X, Khan FU, et al. A novel approach to devise the therapy for ventricular fibrillation by epicardial delivery of lidocaine using active hydraulic ventricular attaching support system: an experimental study in rats. J Biomed Mater Res. 2019;107(5):1722–1731.
   Web of Science ®Google Scholar
• Li X, Mikrani R, Li C, et al. An epicardial delivery of nitroglycerine by active hydraulic ventricular support drug delivery system improves cardiac function in a rat model. Drug Deliv Transl Res. 2020;10(1):23–33.
   PubMed Web of Science ®Google Scholar
• Yue S, Naveed M, Gang W, et al. Cardiac support device (ASD) delivers bone marrow stem cells repetitively to epicardium has promising curative effects in advanced heart failure. Biomed Microdevices. 2018;20(2):40.
   PubMed Web of Science ®Google Scholar
• Liu Z, Naveed M, Baig MMFA, et al. Therapeutic approach for global myocardial injury using bone marrow-derived mesenchymal stem cells by cardiac support device in rats. 2020.DOI:10.20944/preprints202004.0227.v3.
   Google Scholar
• Mikrani R, Li C, Naveed M, et al. Pharmacokinetic Advantage of ASD Device Promote Drug Absorption through the Epicardium. Pharm Res. 2020;37(9):173.
   PubMed Web of Science ®Google Scholar
• Naveed M, Mohammad IS, Xue L, et al. The promising future of ventricular restraint therapy for the management of end-stage heart failure. Biomed Pharmacother. 2018;99:25–32.
   PubMed Web of Science ®Google Scholar
• Mawad D, Mansfield C, Lauto A, et al. A conducting polymer with enhanced electronic stability applied in cardiac models. Sci Adv. 2016;2(11):e1601007.
   PubMed Web of Science ®Google Scholar
• Liang S, Zhang Y, Wang H, et al. Paintable and Rapidly Bondable Conductive Hydrogels as Therapeutic Cardiac Patches. Adv Mater Weinheim. 2018;30(23):e1704235.
   PubMed Web of Science ®Google Scholar
• Wu T, Cui C, Huang Y, et al. Coadministration of an Adhesive Conductive Hydrogel Patch and an Injectable Hydrogel to Treat Myocardial Infarction. ACS Appl Mater Interfaces. 2020;12(2):2039–2048.
   PubMed Web of Science ®Google Scholar
• Lin X, Liu Y, Bai A, et al. A viscoelastic adhesive epicardial patch for treating myocardial infarction. Nat Biomed Eng. 2019;3(8):632–643.
   PubMed Web of Science ®Google Scholar
• Ichihara Y, Kaneko M, Yamahara K, et al. Self-assembling peptide hydrogel enables instant epicardial coating of the heart with mesenchymal stromal cells for the treatment of heart failure. Biomaterials. 2018;154:12–23.
   PubMed Web of Science ®Google Scholar
• Walker BW, Lara RP, Yu CH, et al. Engineering a naturally-derived adhesive and conductive cardiopatch. Biomaterials. 2019;207:89–101.
   PubMed Web of Science ®Google Scholar
• Ungerleider JL, Kammeyer JK, Braden RL, et al. Enzyme-targeted nanoparticles for delivery to ischemic skeletal muscle. Polym Chem. 2017;8(34):5212–5219.
   PubMed Web of Science ®Google Scholar
• Won YW, McGinn AN, Lee M, et al. Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharm. 2013;10(1):378–385.
   PubMedGoogle Scholar
• Rodger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nursing. 2000;31:574–582.
   PubMed Web of Science ®Google Scholar
• Chapman MP, Lopez Gonzalez JL, Goyette BE, et al. Application of the HeartLander crawling robot for injection of a thermally sensitive anti-remodeling agent for myocardial infarction therapy. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:5428–5431.
   PubMedGoogle Scholar
• Wang F, Wang X, Gao L, et al. Nanoparticle-mediated delivery of siRNA into zebrafish heart: a cell-level investigation on the biodistribution and gene silencing effects. Nanoscale. 2019;11(39):18052–18064.
   PubMed Web of Science ®Google Scholar
• Nguyen MA, Wyatt H, Susser L, et al. Delivery of microRNAs by chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS Nano. 2019;13(6):6491–6505.
   PubMed Web of Science ®Google Scholar
• Bejerano T, Etzion S, Elyagon S, et al. Nanoparticle delivery of miRNA-21 mimic to cardiac macrophages improves myocardial remodeling after myocardial infarction. Nano Lett. 2018;18(9):5885–5891.
   PubMed Web of Science ®Google Scholar
• Pechanova O, Barta A, Koneracka M, et al. Protective effects of nanoparticle-loaded aliskiren on cardiovascular system in spontaneously hypertensive rats. Molecules. 2019;24(15):2710.
   Web of Science ®Google Scholar
• Li W, Gong K, Ding Y, et al. Effects of triptolide and methotrexate nanosuspensions on left ventricular remodeling in autoimmune myocarditis rats. Int J Nanomedicine. 2019;14:851–863.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu H, Lu Y, et al. Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury. Int J Nanomedicine. 2019;14:875–888.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation. 2009;119(5):680–686.
   PubMed Web of Science ®Google Scholar
• Moses JW, Nikolsky E, Mehran R, et al. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol. 2006;98(11):1455–1460.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (prospective evaluation in a randomized trial of the safety and efficacy of the use of the TAXUS element paclitaxel-eluting coronary stent system) trial. J Am Coll Cardiol. 2010;56(4):264–271.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Windecker S, Jobe RL, et al. Clinical Outcomes following implantation of thin-strut, bioabsorbable polymer-coated, everolimus-eluting SYNERGY stents. Circ Cardiovasc Interv. 2019;12(9):e008152.
   PubMed Web of Science ®Google Scholar
• Shiozaki AA, Senra T, Morikawa AT, et al. Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles. Clinics. 2016;71(8):435–439.
   PubMed Web of Science ®Google Scholar
• Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380–2389.
   PubMed Web of Science ®Google Scholar
• Kharlamov AN, Feinstein JA, Cramer JA, et al. Plasmonic photothermal therapy of atherosclerosis with nanoparticles: long-term outcomes and safety in NANOM-FIM trial. Future Cardiol. 2017;13(4):345–363.
   PubMed Web of Science ®Google Scholar
• Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114(1):101–108.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. The Lancet. 2016;387(10024):1178–1186.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Yokoyama H, Seto T, et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol. 2007;2(1):65–68.
   PubMed Web of Science ®Google Scholar
• Kunitoh H, Tamura T, Shibata T, et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009;100(3):464–469.
   PubMed Web of Science ®Google Scholar
• Yau TM, Pagani FD, Mancini DM, Chang HL, et al. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure: a randomized clinical trial. JAMA. 2019;321(12):1176–1186.
   PubMed Web of Science ®Google Scholar
• Ascheim DD, Gelijns AC, Goldstein D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014;129(22):2287–2296.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Henry TD, Traverse JH, et al. The RENEW trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina. JACC Cardiovasc Interv. 2016;9(15):1576–1585.
   PubMed Web of Science ®Google Scholar
• Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73.
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Qayyum AA, Jorgensen E, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36(27):1744–1753.
   PubMed Web of Science ®Google Scholar
• Bartunek J, Davison B, Sherman W, et al. Congestive heart failure cardiopoietic regenerative therapy (CHART-1) trial design. Eur J Heart Fail. 2016;18(2):160–168.
   PubMed Web of Science ®Google Scholar
• Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69(5):526–537.
   PubMed Web of Science ®Google Scholar
• Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451–460.
   PubMed Web of Science ®Google Scholar
• Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241–248.
   PubMed Web of Science ®Google Scholar